Upcoming Events

Product Theater

Presentation Title:
An Oral Treatment Option for Advanced Prostate Cancer
Presentation Date and Time:
Thursday, February 17, 2022, 6:00 PM – 6:45 PM PST

Oral Presentations

Presentation Title:
A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-na ve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE
Presentation Date and Time:
Thursday, February 17
1:42 PM – 1:52 PM PST

Poster Presentations

Presentation Title:
Prostate-specific antigen (PSA) outcomes in black (B) and white (W) chemotherapyna-naïve (CN) prostate cancer (PC) patients (pts) treated with enzalutamide (ENZA)
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Treatment (tx) patterns among men with metastatic castration resistant prostate cancer (mCRPC) in the United States (US)​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Treatment trends among men with metastatic castration sensitive prostate cancer (mCSPC): Results from the US component of an international study​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity​​​​​​​
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
Presentation Date and Time:
Thursday, February 17
11:30 AM – 1:00 PM PST

Presentation Title:
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study
Presentation Date and Time:
Thursday, February 17
12:30 PM – 2:00 PM PST

Presentation Title:
Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5)
Presentation Date and Time:
Thursday, February 17
12:30 PM – 2:00 PM PST

Presentation Title:
Avelumab first-line (1L) maintenance + best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis​​​​​​​
Presentation Date and Time:
Thursday, February 17
12:30 PM – 2:00 PM PST

Presentation Title:
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial​​​​​​​
Presentation Date and Time:
Thursday, February 17
12:30 PM – 2:00 PM PST

Presentation Title:
PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States​​​​​​​
Presentation Date and Time:
Friday, February 18
12:30 PM – 2:00 PM PST

Presentation Title:
Avelumab plus axitinib in advanced renal cell carcinoma (aRCC): 12-month interim results from a real-world observational study in the United Kingdom
Presentation Date and Time:
Saturday, February 19
7:00AM – 8:00PM PST

Presentation Title:
Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States​​​​​​​
Presentation Date and Time:
Saturday, February 19
7:00AM – 8:00PM PST

Presentation Title:
Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population​​​​​​​
Presentation Date and Time:
Saturday, February 19
7:00AM – 8:00PM PST